Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials-Reference-Cited by-同舟云学术

Three-year efficacy and safety of new- versus early-generation drug-eluting stents for unprotected left main coronary artery disease insights from the ISAR-LEFT MAIN and ISAR-LEFT MAIN 2 trials

Published:2015-12-22 Issue:7 Volume:105 Page:575-584
ISSN:1861-0684
Container-title:Clinical Research in Cardiology
language:en
Short-container-title:Clin Res Cardiol

Author:

Cassese Salvatore,Kufner Sebastian^ORCID,Xhepa Erion,Byrne Robert A.,Kreutzer Johanna,Ibrahim Tareq,Tiroch Klaus,Valgimigli Marco,Tölg Ralph,Fusaro Massimiliano,Schunkert Heribert,Laugwitz Karl-Ludwig,Mehilli Julinda,Kastrati Adnan

Publisher

Springer Science and Business Media LLC

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s00392-015-0953-x.pdf

Reference34 articles.

1. Stone GW, Moses JW, Leon MB (2007) Left main drug-eluting stents: natural progression or a bridge too far? J Am Coll Cardiol 50(6):498–500. doi: 10.1016/j.jacc.2007.04.055

2. Authors/Task Force m, Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V, Filippatos G, Hamm C, Head SJ, Juni P, Kappetein AP, Kastrati A, Knuuti J, Landmesser U, Laufer G, Neumann FJ, Richter DJ, Schauerte P, Sousa Uva M, Stefanini GG, Taggart DP, Torracca L, Valgimigli M, Wijns W, Witkowski A (2014) 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). Eur Heart J 35(37):2541–2619. doi: 10.1093/eurheartj/ehu278

3. Bittl JA, He Y, Jacobs AK, Yancy CW, Normand SL, American College of Cardiology Foundation/American Heart Association Task Force on Practice G (2013) Bayesian methods affirm the use of percutaneous coronary intervention to improve survival in patients with unprotected left main coronary artery disease. Circulation 127(22):2177–2185. doi: 10.1161/CIRCULATIONAHA.112.000646

4. Athappan G, Patvardhan E, Tuzcu ME, Ellis S, Whitlow P, Kapadia SR (2013) Left main coronary artery stenosis: a meta-analysis of drug-eluting stents versus coronary artery bypass grafting. JACC Cardiovasc Interv 6(12):1219–1230. doi: 10.1016/j.jcin.2013.07.008

5. Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, King LA, Fusaro M, Laugwitz KL, Kastrati A (2014) Incidence and predictors of restenosis after coronary stenting in 10,004 patients with surveillance angiography. Heart 100(2):153–159. doi: 10.1136/heartjnl-2013-304933

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers Associated with Immune Checkpoint, N6-Methyladenosine, and Ferroptosis in Patients with Restenosis;Journal of Inflammation Research;2023-02

2. Evolution of Treatment Tactics for Patients with Trunk Lesions of Coronary Arteries;Ukraïnsʹkij žurnal medicini, bìologìï ta sportu;2022-12-28

3. New Insights Into Long- Versus Short-Term Dual Antiplatelet Therapy Duration in Patients After Stenting for Left Main Coronary Artery Disease: Findings From a Prospective Observational Study;Circulation: Cardiovascular Interventions;2022-06

4. A Case Summary of the Application of a Drug-Eluting Stent Combined with a Drug-Coated Balloon in Left Main Coronary Artery Disease;Cardiovascular Innovations and Applications;2021

5. Long‐term outcome in patients treated with first‐ versus second‐generation drug‐eluting stents for the treatment of unprotected left main coronary artery stenosis;Catheterization and Cardiovascular Interventions;2019-07-13